References
- Narayana A, Vaughan AT, Gunaratne S, Kathuria S, Walter SA, Reddy SP. Is p53 an independent prognostic factor in patients with laryngeal cancinoma?. Cancer 1998; 82: 286–91
- Vlachtsis K, Nikolaou A, Markou K, Fountzilas G, Daniilidis I. Clinical and molecular prognostic factors in operable laryngeal cancer. Eur Arch Otorhinolaryngol 2005; 262: 890–8
- Welkoborsky HJ, Hinni M, Dienes HP, Mann WJ. Predicting recurrence and survival in patients with laryngeal cancer by means of DNA cytometry, tumor front grading, and proliferation markers. Ann Otol Rhinol Laryngol 1995; 104: 503–10
- Parikh RR, Yang Q, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer 2007; 109: 566–73
- Díez M, Ramos P, Medrano MJ, Mugüerza JM, Villeta R, Lozano O, et al. Preoperatively irradiated rectal carcinoma: analysis of the histopathologic response and predictive value of proliferating cell nuclear antigen immunostaining. Oncology 2003; 64: 213–19
- Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8: 885–92
- Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA, García-Aguilar J. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000; 43: 451–9
- Tsai ST, Jin YT, Leung HW, Wang ST, Tsao CJ, Su IJ. Bcl-2 and proliferating cell nuclear antigen (PCNA) expression correlates with subsequent local recurrence in nasopharyngeal carcinomas. Anticancer Res 1998; 18: 2849–54
- Lane DP. p53 the guardian of the genome. Nature 1992; 358: 15–16
- Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AL. Activation mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half life. Mol Cell Biol 1988; 8: 531
- Rucci L, Bocciolini C, Franchi A, Ferlito A, Casucci A. Epidermal growth factor receptor and p53 expression in T1-T2 glottic cancer involving the anterior or posterior commissure. Acta Otolaryngol 2004; 124: 102–6
- Krecicki T, Jelen M, Zalesska-Krecicka M, Rak J, Szkudlarek T, Jelen-Krzeszewska J. Epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and Ki-67 antigen in laryngeal epithelial lesions. Oral Oncol 1999; 35: 180–6
- Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978; 121: 2228–34
- Buyukbayram H, Cureoglu S, Arslan A, Isikakdogan AR. Prognostic value of PCNA and mutant p53 expression in laryngeal squamous cell carcinoma. Cancer Invest 2004; 22: 195–202
- Resnick JM, Uhlman D, Niehans GA, Gapany M, Adams G, Knapp D, et al. Cervical lymph node status and survival in laryngeal carcinoma: prognostic factors. Ann Otol Rhinol Laryngol 1995; 104(9 Pt 1)685–94
- Mielcarek-Kuchta D, Olofsson J, Golusinski W. p53, Ki67 and cyclin D1 as prognosticators of lymph node metastases in laryngeal carcinoma. Eur Arch Otorhinolaryngol 2003; 260: 549–54
- Tan LKS, Ogden GR. p53 over-expression in laryngeal carcinoma is not predictive of response to radiotherapy. Oral Oncol 1997; 33: 177–81
- Almadori G, Cadoni G, Galli J, Ferrandina G, Scambia G, Exarchakos G, et al. Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse. Int J Cancer 1999; 84: 188–91
- Dobros W, Rys J, Niezabitowski A, Olszewski E. The prognostic value of proliferating cell nuclear antigen (PCNA) in the advanced cancer of larynx. Auris Nasus Larynx 1998; 25: 295–301
- Krecicki T, Jelen M, Zalesska-Krecicka M, Szkudlarek T, Szajowski K. Immunohistochemically stained markers (p53, PCNA, bcl-2) in dysplastic lesions of the larynx. Cancer Lett 1999; 143: 23–8